NCT04643561

Using Travelan to Boost Immune Response in Vitro to COVID-19

A Feasibility Trial Using Trevalan in Healthy Volunteers for Increasing an in Vitro Immune Response to COVID-19 Proteins

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The gut immune system was shown as an effective target for inducing systemic immune signals against viruses. Oral administration of Travelan, an over the counter product which contains hyperimmune bovine colostrum was shown in preclinical studies to augment the anti-viral immune towards several strains of influenza viruses (RNA viruses). This study will evaluate the option that Trevalan may help improve the immune system reaction when introduced to COVID-19 proteins in-vitro. 5 healthy volunteers will receive a treatment regimen of 5 days with Trevalan. Before and after treatment, blood samples will be taken in order to test immune response towards viral proteins of the COVID-19 virus in vitro by measuring the number of T cell clone secreting IFNγ against viral antigens.

Conditions

• Covid19

Interventions

Type	Name	Description
OTHER	Travelan OTC	5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention

Timeline

• Start date: 2020-11-01
• Primary completion: 2020-12-31
• Completion: 2020-12-31
• First posted: 2020-11-25
• Last updated: 2020-11-27

Locations

1 site across 1 country: Israel